Mouse models of systemic candidiasis and pulmonary and systemic aspergillosis were established by using DBA/2N mice, which are known to be deficient in the C5 component of complement. In experiments comparing lethality in the respective models in DBA/2N versus outbred CFW mice, results showed that the 50% lethal dose values for the DBA/2N mice were 10-to 1,000-fold lower than those for the outbred mice, depending on the experiment. Additionally, onset of death was somewhat delayed for the DBA/2N mice. In the case of the pulmonary aspergillosis model, administration of cortisone acetate was necessary to ensure lethality after intranasal infection, but only a single dose was necessary.
Candidiasis and aspergillosis are the preeminent examples of opportunistic mycoses, occurring in people with underlying disorders but rarely in individuals with intact immune capabilities. This is despite the fact that the majority of people either are carriers of Candida species or are environmentally exposed to Aspergillus conidia on a regular basis. Thus, it is not surprising that in order to establish infection in mice with intact immune responses, either overwhelming numbers of fungal propagules must be used or the animals must be compromised in some fashion, which makes the application of mouse models for evaluation of antifungal agents problematic (5, 13, (15) (16) (17) . Mouse models for systemic candidiasis and pulmonary aspergillosis were established a number of years ago (1, 17) and have been used in the intervening years with little variation. We sought to develop models in which mortalities could be induced with lower infecting doses, thereby making the model less severe.
Male DBA/2N mice, 21 to 23 g (average weight), 8 to 10 weeks old (Simonsen Laboratories, Gilroy, Calif.), and outbred male CFW mice, 23 to 25 g (average weight), 7 to 9 weeks old (Charles River Breeding Laboratories, Inc., Portage, Mich.), were used for all experiments.
For preparation of inoculum, frozen suspensions of Candida albicans B311 (originally obtained from H. Hasenclever, National Institutes of Health) were transferred to 2% glucose-1% yeast extract (GYE) broth for incubation with shaking at 37°C overnight. Conidia of Aspergillus fumigatus ATCC 13073 were obtained by culturing the fungus on GYE agar at 37°C for 7 to 10 days; the conidia were dislodged from the surface by adding 10 ml of sterile water with 0.05% Tween 80 to the petri plate and moving a spinning magnetic stir bar over the mycelial mat. The conidia were harvested and stored in water at 4°C until needed. of infection less acute than that seen with the outbred mice but still highly lethal.
For both strains of mice, a short-term organ load assay was conducted with groups of eight mice each which were infected intravenously with 2.5 x i04 CFU of C. albicans.
Kidneys were removed 72 h after infection (at this interval, no mice in either group had died) and homogenized in 10 ml of sterile phosphate-buffered saline by using a tissue homogenizer (Brinkman Instruments, Inc., Westbury, N.Y.), and serial dilutions were made and plated in a quantitative fashion on the surface of Sabouraud dextrose agar containing 50 ,ug of chloramphenicol per ml. After overnight incubation at 37°C, colonies were enumerated, and data were calculated as the log1o per gram of tissue ± standard error, with results of 3.79 ± 0.26 and 6.89 ± 0.06 for CFW and DBA/2N mice, respectively. These results were significantly different at the P = 0.05 level when analyzed by Box's small sample F approximation (2).
After 6 days, kidney specimens for histopathology were removed from mice of both strains infected intravenously with 2.0 x 104 CFU of C. albicans and submitted in a blind fashion to an independent pathology service for comparative assessment. While the pathology, consisting of interstitial lesions of neutrophils and histiocytes distributed without respect to the renal architecture, was similar in both the CFW and DBA/2N kidneys, the lesions were estimated to involve approximately 10 to 15% of the mass in CFW mice but nearly 30% of the kidney mass in DBA/2N mice. Additionally, while only occasional blastospore forms of the yeast cells were seen in CFW mice, numerous yeast cells and pseudohyphae were seen in DBA/2N mice (not shown).
Aspergillosis. DBA/2N and CFW mice were compared in a 50% lethal dose experiment using a pulmonary model of aspergillosis in which animals were infected intranasally 18 h after receiving a single dose of 5 is established in DBA/2N mice than in the outbred CFW mice. In infected DBA/2N mice in which no cortisone acetate was administered and in uninfected DBA/2N mice in which cortisone was administered, no deaths occurred (data not shown). Additionally, when two lower dosage levels of cortisone acetate were used in DBA/2N mice, mortalities were greatly reduced compared with those seen at the 5-mg-dose level (Fig. 3) .
Lung specimens from DBAI2N mice removed 6 days after intranasal infection were examined for histopathology; they showed suppurative bronchitis and mild focal pneumonia associated with hyphae. Many of the bronchi and some of the alveoli and peribronchial connective tissue contained an exudate composed of neutrophils undergoing necrosis. A typical pattern of dichotomously branching hyphae and an occasional fungus ball were seen in the sections (not shown).
For comparisons in a systemic model of aspergillosis, intravenous infection with graded doses of A. fumigatus conidia was used to infect mice not pretreated with cortisone acetate. The margin of difference in 50% lethal dose values for the two strains of mice are, however, similar in onset and rate of deaths (Fig. 4) .
Our findings of reduced requirements for inoculum and pretreatment with cortisone acetate with DBA/2N mice in the pulmonary model of aspergillosis should offer an improved situation over previous models. In the recent report of Dixon et al. (3) , the investigators explored the relationship of infecting dose and severity of immunocompromising regimen in a mouse model of pulmonary aspergillosis, concluding that a moderate degree of immunosuppression is essential and that inoculum concentrations of 108 or greater are necessary to achieve mortalities approaching 100%. With this approach, the onset of death was extremely rapid, with most deaths occurring in the first 72 h. With the application of such a model for the assessment of antifungal drugs, the ability of compounds administered in reasonable doses to reduce mortality becomes severely encumbered. Similarly, with models of systemic candidiasis in immunecompetent animals, many investigators have used infective doses of C. albicans of up to 106 CFU administered intravenously (4, 9, 16), which established disease with an acute course. In a fashion analogous to that for aspergillosis, administration of compromising agents can increase the severity of disease or lower the infecting dose necessary to induce serious disease (6) . However, the use of such agents causes secondary effects which are difficult to control, including negative interactions with some antifungal drugs (5, 11) .
It was our aim to establish models of mycoses using animals with known immune defects in which reproducible disease could be established with lower inoculum levels, resulting in a less acute course. Recently, the application of the DBA/2N candidiasis model in the evaluation of several antifungal drugs by our group enabled differentiation between the fungistatic effects of several azoles and the fungicidal effects of amphotericin B (8) .
The role of the C5 component of complement in an innate response to candidiasis and cryptococcosis has been established (7, 12, 14) , but little information on the role of C5 in aspergillosis is available. The results presented herein invite additional study to further define the role of activated C5 in the recruitment of inflammatory cells in the latter model. It is clear from the data reported herein, however, that some degree of immunosuppression is still necessary.
In summary, we have developed models of candidiasis and aspergillosis using DBA/2N mice, which are known to be deficient in the C5 component of complement. These models require less infecting inoculum and follow a less acute course than previous models with outbred strains of mice and may therefore be useful in preclinical trials involving antifungal agents or other agents influencing the course of disease.
